Basic Information
Ebixa
Regulatory Information
EMEA/H/C/000463
Authorised
May 15, 2002
26
January 5, 2022
Company Information
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of patients with moderate to severe Alzheimer's disease.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Ebixa. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ebixa.